title: Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet: probiotics, prebiotics and the low FODMAP diet.
abstract: Irritable bowel syndrome (IBS) is a functional bowel disorder characterised by abdominal pain or discomfort with disordered defecation. This review describes the role of the gastrointestinal (GI) microbiota in the pathogenesis of IBS and how dietary strategies to manage symptoms impact on the microbial community. Evidence suggests a dysbiosis of the luminal and mucosal colonic microbiota in IBS, frequently characterised by a reduction in species of Bifidobacteria which has been associated with worse symptom profile. Probiotic supplementation trials suggest intentional modulation of the GI microbiota may be effective in treating IBS. A smaller number of prebiotic supplementation studies have also demonstrated effectiveness in IBS whilst increasing Bifidobacteria. In contrast, a novel method of managing IBS symptoms is the restriction of short-chain fermentable carbohydrates (low fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet). Studies consistently demonstrate clinical effectiveness of the low FODMAP diet in patients with IBS. However, one unintentional consequence of this dietary intervention is its impact on the microbiota. This leads to an interesting paradox; namely, increasing luminal Bifidobacteria through probiotic supplementation is associated with a reduction in IBS symptoms while in direct conflict to this, the low FODMAP diet has clinical efficacy but markedly reduces luminal Bifidobacteria concentration. Given the multifactorial aetiology of IBS, the heterogeneity of symptoms and the complex and diverse nature of the microbiome, it is probable that both interventions are effective in patient subgroups. However combination treatment has never been explored and as such, presents an exciting opportunity for optimising clinical management, whilst preventing potentially deleterious effects on the GI microbiota.
authors.affiliation: King's College London,Diabetes and Nutritional Sciences Division,London SE1 9NH,UK.
authors.forename: Heidi M
authors.initials: HM
authors.lastname: Staudacher
authors.affiliation: King's College London,Diabetes and Nutritional Sciences Division,London SE1 9NH,UK.
authors.forename: Kevin
authors.initials: K
authors.lastname: Whelan
mesh_terms: D004032:Diet; D004187:Disaccharides / Q000008:administration & dosage; D000069196:Gastrointestinal Microbiome; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000382:microbiology* / Q000628:therapy; D015201:Meta-Analysis as Topic; D009005:Monosaccharides / Q000008:administration & dosage; D064887:Observational Studies as Topic; D009844:Oligosaccharides / Q000008:administration & dosage; D011108:Polymers / Q000008:administration & dosage; D056692:Prebiotics / Q000008:administration & dosage*; D019936:Probiotics / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic
chemical_list: D004187:Disaccharides; D009005:Monosaccharides; D009844:Oligosaccharides; D011108:Polymers; D056692:Prebiotics; C024617:polyol
keywords: FODMAP; FODMAP fermentable oligosaccharides; GI gastrointestinal; GOS galacto-oligosaccharides; IBS irritable bowel syndrome; IBS-D diarrhoea-predominant IBS; Irritable bowel syndrome; Prebiotic; Probiotic; RCT randomised control trial; disaccharides; monosaccharides and polyols